Table 5.

Summary of phase 1/2 safety reporting results for ChAdOx1 nCoV-19, Ad5-nCoV, mRNA-1273, and BNT-162.

Vaccine and dose	Number tested	Pain (%)	Fatigue (%)	Headache (%)	Myalgia (%)	Fever ≥38°C (%)	Serious adverse event
ChAdOx1 nCoV-19 (phase 1/2) (91)
1 dose 5 × 1010 v.p. (no PCM)	487	67	70	68	60	18	0
1 dose 5 × 1010 v.p. (with PCM)	56	50	71	61	48	16	0
Ad-5 nCoV (phase 1) (92)
1 dose 5 × 1010 v.p.	36	47	47	39	19	42	0
1 dose 1 × 1011 v.p.	36	56	39	31	8	42	0
1 dose 1.5 × 1011 v.p.	36	58	44	47	22	56	0
Ad-5 nCoV (phase 2) (93)
1 dose 5 × 1010 v.p.	129	56	34	28	18	16	0
1 dose 1 × 1011 v.p.	253	57	42	29	15	32	0
mRNA-1273 (phase 1) (94)
2 doses 25 μg	13	77	39	23	23	0	0
2 doses 100 μg	15	100	80	60	53	40	0
2 doses 250 μg	14	100	57	93	86	57	0
BNT162b1 (phase 1) (95)
2 doses 10 μg	12	83	66	83	41	8.3	0
2 doses 30 μg	12	100	83	100	59	75	0
1 dose 100 μg	12	100	84	75	58	50	0
Whole inactivated alum adjuvanted vaccine (phase 1) (89)
3 doses 2.5 μg	24	21	0	0	0	0	0
3 doses 5 μg	24	4	4	0	0	4	0
3 doses 10 μg	24	25	0	0	0	4	0
Whole inactivated alum adjuvanted vaccine (phase 2) (89)
2 doses 5 μg day 0 and 14	84	2	1	1	0	5	0
2 doses 5 μg day 0 and 21	84	14	0	0	0	2	0
NVX-CoV2373/Matrix-M1 (phase 1) (90)
2 doses 5 μg + 50 μg Matrix-M1	25	58	47	47	45	0	0
2 doses 25 μg + 50 μg Matrix-M1	25	62	50	58	55	4	0
2 doses 25 μg no adjuvant	25	8	12	28	9	0	0

Results for the 2 or 3 dose schedules show reported results after the final dose. Values approximated where data presented as figures. PCM, paracetamol; v.p., viral particles.